Results 11 to 20 of about 35,120,764 (296)

Programmed cell death-1 and programmed cell death ligand-1 antibodies-induced dysthyroidism [PDF]

Endocrine Connections, 2018
Background: Monoclonal antibodies blocking the programmed cell death-1 (PD-1) or its ligand (PD-L1) are a group of immune checkpoints inhibitors (ICIs) with proven antitumor efficacy.
Jaafar Jaafar, Eugenio Fernandez, Heba Alwan, Jacques Philippe   +3 more
doaj   +5 more sources

Association of disease activity with programmed cell death 1 and its ligand programmed cell death ligand 1 expressions in lupus patients

Indian Journal of Rheumatology, 2022
Background: Programmed cell death 1(PD-1)/programmed cell death ligand 1 (PD-L1) pathway is an immune checkpoint implicated in immune tolerance and involved in the pathogenesis of several autoimmune diseases.
Eman Eissa, Rania Kandil, Nehal El-Ghobashy, Walaa Abdelfattah, Zainab Hammouda, Sara Medhat Gadelsayed, Faten Bayoumi   +6 more
doaj   +2 more sources

Programmed Cell Death-1/Programmed Death-ligand 1 Pathway: A New Target for Sepsis

Chinese Medical Journal, 2017
Objective: Sepsis remains a leading cause of death in many Intensive Care Units worldwide. Immunosuppression has been a primary focus of sepsis research as a key pathophysiological mechanism.
Qiang Liu, Chun-Sheng Li
doaj   +3 more sources

Programmed cell death protein 1 (PD-1) / programmed cell death ligand 1 (PD-L1) in multiple myeloma [PDF]

Journal of the Egyptian National Cancer Institute
Background The bone marrow microenvironment in multiple myeloma (MM) is characterized by complex immune dysregulation involving multiple inhibitory pathways.
Shimaa El-Garf, Reham Hammad, Eman Kandeel, Ahmed Rabea, Mona Alrayes   +4 more
doaj   +2 more sources

Programmed Cell Death-1/Programmed Cell Death-1 Ligand as Prognostic Markers of Coronavirus Disease 2019 Severity

Cells, 2022
Current research proves that immune dysregulation is a common feature of coronavirus disease 2019 (COVID-19), and immune exhaustion is associated with increased disease mortality.
Paulina Niedźwiedzka-Rystwej, Adam Majchrzak, Bogusz Aksak-Wąs, Karol Serwin, Zenon Czajkowski, Ewelina Grywalska, Izabela Korona-Głowniak, Jacek Roliński, Miłosz Parczewski   +8 more
doaj   +3 more sources

Catching up with solid tumor oncology: what is the evidence for a prognostic role of programmed cell death-ligand 1/programmed cell death-1 expression in B-cell lymphomas? [PDF]

Haematologica, 2016
Therapeutic strategies targeting the programmed cell death-ligand 1/programmed cell death-1 pathway have shown significant responses and good tolerability in solid malignancies.
Fabienne McClanahan, Thomas G. Sharp, John G. Gribben   +2 more
doaj   +2 more sources

Correlation of E-cadherin, vimentin, CD206, programmed cell death receptor 1, and programmed cell death ligand 1 expressions with clinicopathological factors and prognosis in oral squamous cell carcinoma [PDF]

Journal of International Medical Research
Objective Oral squamous cell carcinoma is the most common malignant tumor occurring in the head and neck region. Current treatment principles are based on radical surgery, supplemented by radiotherapy and chemotherapy.
Zheng-Yi Lai, Jie Ma, Jia-Yi Yin, Xiu-An Zhu, Jing-Ping Zhou, De-Tao Tao   +5 more
doaj   +2 more sources

Soluble programmed cell death protein-1 and programmed cell death ligand-1 in sepsis [PDF]

Critical Care, 2018
Debasree Banerjee, Sean Monaghan, Runping Zhao, Thomas Walsh, Amy Palmisciano, Gary S. Phillips, Steven Opal, Mitchell M. Levy   +7 more
doaj   +3 more sources

Assessment of programmed cell death 1 and its programmed cell death ligand 1 levels in vitiligo

Journal of the Egyptian Women’s Dermatologic Society
Background Programmed cell death 1 (PD-1) is a cell surface protein that serves as an immune checkpoint in conjunction with its two ligands, PD-L1 and PD-L2.
Hanan R. Nada, Ahmed Mourad, Laila A. Rashed, Ghada M. El-Hanafy, Nermeen M.A. Abdallah, Mohamed M. Abdelhady   +5 more
doaj   +2 more sources

Inhibitory Immune Checkpoints beyond Programmed Cell Death Ligand 1 in Merkel Cell Carcinoma: Abundant Expression of TIGIT Independent of the Presence of Merkel Cell Polyoma Virus [PDF]

Acta Dermato-Venereologica
Merkel cell carcinoma is a rare, aggressive skin cancer in which Merkel cell polyoma virus (MCPyV) is frequently pathogenically involved. After failure of anti-programmed cell death protein 1/programmed cell death ligand 1 immunotherapy, therapeutic ...
Ferdinand Toberer, Julia K. Winkler, Leroy Atienza Fernandez, Lea Adams, Alexander Brobeil, Marcell Tóth, Alexander H. Enk, Jürgen C. Becker, Anke Lonsdorf   +8 more
doaj   +2 more sources